SCHEMBL3306367

SCHEMBL3306367

Cc1ccc(S(=O)(=O)NC[C]=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.66
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
CA12 O43570 2/20 0.56
CA9 Q16790 2/20 0.56
GBA1 P04062 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
ATM Q13315 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.55
GAA P10253 1/20 0.55
CYP19A1 P11511 1/20 0.54
TSHR P16473 1/20 0.54
CA2 P00918 2/20 0.53
CA1 P00915 1/20 0.53
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2624207 0.82 ALDH1A1 (0.63) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL967916 0.82 ALDH1A1 (0.63) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL5522232 0.82 ALDH1A1 (0.57) ALDH1A1CA12CA9GBA1CYP1A2
SCHEMBL5567042 0.81 ALDH1A1 (0.75) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL19466252 0.81 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL3729538 0.80 ALDH1A1 (0.66) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL8213969 0.79 ALDH1A1 (0.72) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL126985 0.79 ALDH1A1 (1.00) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL6579638 0.78 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL30667700 0.78 ALDH1A1 (0.58) ALDH1A1MEN1KMT2ACA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099875-A1 NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS PHOSPHOENIX SARL (FR) 2010-04-22 US claimed
EP-1310510-B1 Topologically segregated, encoded solid phase libraries AVENTIS PHARMA INC (US) 2007-07-11 EP claimed
EP-1310510-A2 Topologically segregated, encoded solid phase libraries SELECTIDE CORPORATION (US) 2003-05-14 EP claimed
EP-0705279-B1 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORP (US) 2003-02-19 EP claimed
US-6090912-A MULTIPLICITY OF SEPARATE SOLID SUPPORTS WITH SURFACE HAVING SUCEPTIBLE LINKER TO SINGLE SPECIES OF TEST COMPOUND AND WITH INTERIOR HAVING ATTACHED NON-CLEAVABLE CODING MOLECULE; FOR SCREENING LIGANDS OR ACCEPTORS SELECTIDE CORPORATION (US) 2000-07-18 US claimed
EP-0705279-A4 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORP (US) 1999-03-24 EP claimed
US-5840485-A SYNTHETIC TEST COMPOUNDS ATTACHED TO SEPARATE PHASE SYNTHESIS SUPPORTS THAT ALSO CONTAIN CODING MOLECULES THAT ENCODE THE STRUCTURE OF THE SYNTHETIC TEST COMPOUND SELECTIDE CORPORATION (US) 1998-11-24 US claimed
EP-0442843-B1 Inhibitors for the anticoagulant pretreatment of blood samples PENTAPHARM AG (CH) 1998-09-09 EP claimed
EP-0705279-A1 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORPORATION (US) 1996-04-10 EP claimed
WO-1994028028-A1 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORPORATION (US) 1994-12-08 WO claimed
US-5187102-A Treating blood sample with thrombin inhibitor which does not bind bivalent cations PENTAPHARM AG (CH) 1993-02-16 US claimed
US-20100099875-A1 NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS PHOSPHOENIX SARL (FR) 2010-04-22 US disclosed
EP-1310510-B1 Topologically segregated, encoded solid phase libraries AVENTIS PHARMA INC (US) 2007-07-11 EP disclosed
EP-1310510-A2 Topologically segregated, encoded solid phase libraries SELECTIDE CORPORATION (US) 2003-05-14 EP disclosed
EP-0705279-B1 TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES SELECTIDE CORP (US) 2003-02-19 EP disclosed
US-5229386-A Anticoagulants, hypotensive agents, antiallergens, antiinflammatory agents FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-07-20 US disclosed
US-5187102-A Treating blood sample with thrombin inhibitor which does not bind bivalent cations PENTAPHARM AG (CH) 1993-02-16 US disclosed
US-5145860-A Anticoagulants, vasodilators, antiinflammatory, antiallergens, enzyme inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-09-08 US disclosed
EP-0388909-A2 Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099875-A1 NEW ORTHO-FUNCTIONALIZED P-CHIRAL ARYLPHOSPHINES AND DERIVATIVES: THEIR PREPARATION AND USE IN ASYMMETRIC CATALYSIS PNP, NANP, PHOSPHO1 ALDH1A1 834/4885MEN1 4315/4885KMT2A 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.